DK9290D0 - Praeparat, isaer til forhindring af infektioner hos dyr - Google Patents

Praeparat, isaer til forhindring af infektioner hos dyr

Info

Publication number
DK9290D0
DK9290D0 DK009290A DK9290A DK9290D0 DK 9290 D0 DK9290 D0 DK 9290D0 DK 009290 A DK009290 A DK 009290A DK 9290 A DK9290 A DK 9290A DK 9290 D0 DK9290 D0 DK 9290D0
Authority
DK
Denmark
Prior art keywords
csf
isaar
prevention
preparation
genetically engineered
Prior art date
Application number
DK009290A
Other languages
English (en)
Other versions
DK175245B1 (da
DK9290A (da
Inventor
Thomas C Boone
Allan L Miller
Jeffrey W Andresen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DK9290D0 publication Critical patent/DK9290D0/da
Publication of DK9290A publication Critical patent/DK9290A/da
Application granted granted Critical
Publication of DK175245B1 publication Critical patent/DK175245B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Filling Or Discharging Of Gas Storage Vessels (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
  • Element Separation (AREA)
DK199000092A 1988-05-13 1990-01-12 Fremgangsmåde til isolering og rensning af granulocyt kolonistimulerende faktor (G-CSF) fra en mikroorganisme, der producerer rekombinant G-CSF DK175245B1 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US19385788A 1988-05-13 1988-05-13
US19385788 1988-05-13
US34801189A 1989-05-09 1989-05-09
US34801189 1989-05-09
PCT/US1989/002057 WO1989010932A1 (en) 1988-05-13 1989-05-12 Compositions and method for treating or preventing infections in animals
US8902057 1989-05-12

Publications (3)

Publication Number Publication Date
DK9290D0 true DK9290D0 (da) 1990-01-12
DK9290A DK9290A (da) 1990-03-09
DK175245B1 DK175245B1 (da) 2004-07-19

Family

ID=26889429

Family Applications (1)

Application Number Title Priority Date Filing Date
DK199000092A DK175245B1 (da) 1988-05-13 1990-01-12 Fremgangsmåde til isolering og rensning af granulocyt kolonistimulerende faktor (G-CSF) fra en mikroorganisme, der producerer rekombinant G-CSF

Country Status (12)

Country Link
US (1) US5849883A (da)
EP (2) EP0347041A3 (da)
JP (1) JP2796388B2 (da)
KR (1) KR0133561B1 (da)
AT (1) ATE452190T1 (da)
AU (3) AU636127B2 (da)
DE (1) DE68929566D1 (da)
DK (1) DK175245B1 (da)
FI (1) FI900178A0 (da)
NO (1) NO300217B1 (da)
NZ (1) NZ229098A (da)
WO (1) WO1989010932A1 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
DE68929566D1 (de) 1988-05-13 2010-01-28 Amgen Inc Verfahren zur Isolierung und Reinigung von G-CSF
EP0648501A1 (en) * 1989-10-10 1995-04-19 Amgen Inc. Compositions comprising G-CSF for treating or preventing infections in canine and feline animals
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5336488A (en) * 1991-08-07 1994-08-09 American Cyanamid Company Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
CA2197650A1 (en) * 1994-08-19 1996-02-29 Hong Liu Method of treating birds with avian myelomonocytic growth factor
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996040912A1 (en) 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
DE69915204T2 (de) * 1998-08-17 2004-07-29 Pfizer Products Inc., Groton Stabilisierte Proteinzusammensetzung
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
JP3544180B2 (ja) 2000-02-29 2004-07-21 ファイザー・プロダクツ・インク 安定化した顆粒球コロニー刺激因子
AU9096001A (en) * 2000-09-08 2002-03-22 Amgen Inc G-csf analog compositions and methods
US7557195B2 (en) 2002-03-20 2009-07-07 Biopolymed, Inc. Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF
WO2004001056A1 (en) * 2002-06-24 2003-12-31 Dr. Reddy's Laboratories Ltd. Process for preparing g-csf
JP2006526016A (ja) * 2003-05-09 2006-11-16 シエーリング アクチエンゲゼルシャフト 炎症性呼吸器疾患の治療
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
EP1789440A4 (en) 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
JP2007525495A (ja) 2004-02-11 2007-09-06 アミリン・ファーマシューティカルズ，インコーポレイテッド 選択可能な特性を有するハイブリッドポリペプチド
WO2006083254A1 (en) 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
CN101035806A (zh) 2004-10-08 2007-09-12 安米林药品公司 新的糊精家族多肽－6（afp－6）类似物和制备和使用它们的方法
EP1817047B1 (en) 2004-11-05 2012-02-08 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
BRPI0518559A2 (pt) 2004-12-13 2008-11-25 Amylin Pharmaceuticals Inc motivos da famÍlia do polipetÍdeo pancreÁtico, polipeptÍdeos e mÉtodos compreendendo os mesmos
JP2008530130A (ja) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
MX2007015156A (es) 2005-06-01 2008-02-15 Maxygen Holdings Ltd Polipeptidos g-csf pegilados y metodos para la produccion de los mismos.
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
KR100735784B1 (ko) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
CA2617649A1 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
DE102006009437A1 (de) 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
US9176145B2 (en) 2006-07-21 2015-11-03 Femalon S.P.R.L. Kit for predicting implantation success in assisted fertilization
WO2008116470A1 (en) * 2007-03-26 2008-10-02 Drugrecure Aps Enhancing pulmonary host defence via administration of granulocyte- colony stimulating factor
BRPI0815975B8 (pt) 2007-08-27 2021-05-25 Biogenerix Ag preparação aquosa, recipiente farmacêutico, processo para preparar uma preparação aquosa, e, uso de uma preparação aquosa
JP5168604B2 (ja) 2008-05-08 2013-03-21 味の素株式会社 タンパク質のリフォールディング方法
BRPI0916515B8 (pt) * 2008-07-23 2021-07-27 Ambrx Inc polipeptídeo de fator estimulante de colônias de granulócitos bovino (bg-csf), formulação farmacêutica e composição compreendendo o mesmo
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
WO2011005488A1 (en) 2009-06-22 2011-01-13 Amgen Inc. Refolding proteins using a chemically controlled redox state
CA2765154A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
AU2010341518B2 (en) 2009-12-21 2014-01-09 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
WO2011113601A1 (en) 2010-03-17 2011-09-22 Biogenerix Ag Method for obtaining biologically active recombinant human g-csf
RU2487885C2 (ru) * 2010-07-20 2013-07-20 Зао "Биокад" Способ крупномасштабного получения, выделения и очистки рекомбинантного гранулоцитарного колониестимулирующего фактора человека
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
WO2012112940A1 (en) 2011-02-18 2012-08-23 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
HUP1200172A2 (en) * 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
EP2855517A1 (en) 2012-05-29 2015-04-08 Novo Nordisk A/S Pancreatic polypeptide compounds and use
EP2978770B1 (en) 2013-03-29 2019-11-06 Dr. Reddy's Laboratories Limited Refolding of proteins
KR102461760B1 (ko) * 2017-10-11 2022-10-31 엘랑코 유에스 인코포레이티드 돼지 g-csf 변이체 및 그 용도
WO2020234742A1 (en) * 2019-05-20 2020-11-26 Lupin Limited Granulocyte colony stimulating factor purification
JP2022543536A (ja) * 2019-07-09 2022-10-13 タンベックス バイオファーマ ユーエスエー，インコーポレイティド 温度制御下における顆粒球コロニー刺激因子の精製

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2438821A1 (fr) * 1978-10-13 1980-05-09 France Etat Dispositif d'allumage a fil chaud de securite
US4618600A (en) * 1984-04-19 1986-10-21 Biotechnology Research Associates, J.V. Novel polypeptide diuretic/vasodilators
JPS6145010A (ja) * 1984-08-08 1986-03-04 Setsuji Umezaki 埋立地の造成方法
JPH0615477B2 (ja) * 1985-02-08 1994-03-02 中外製薬株式会社 感染防禦剤
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4721420A (en) * 1985-09-03 1988-01-26 Arthur D. Little, Inc. Pipeline transportation of coarse coal-liquid carbon dioxide slurry
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
AU621051B2 (en) * 1987-04-28 1992-03-05 Amgen, Inc. Method for purifying granulocyte-macrophage colony stimulating factor
ES2070855T5 (es) * 1987-10-23 2004-03-01 Schering Corporation Metodo para purificar una proteina.
DE68929566D1 (de) 1988-05-13 2010-01-28 Amgen Inc Verfahren zur Isolierung und Reinigung von G-CSF

Also Published As

Publication number Publication date
AU4781290A (en) 1990-11-15
EP0719860A1 (en) 1996-07-03
KR0133561B1 (ko) 1998-04-21
AU661172B2 (en) 1995-07-13
AU4197293A (en) 1993-10-28
DK175245B1 (da) 2004-07-19
JP2796388B2 (ja) 1998-09-10
EP0347041A3 (en) 1990-11-22
DK9290A (da) 1990-03-09
WO1989010932A1 (en) 1989-11-16
FI900178A0 (fi) 1990-01-12
EP0719860B1 (en) 2009-12-16
KR900701824A (ko) 1990-12-04
NO300217B1 (no) 1997-04-28
AU4197393A (en) 1993-10-28
EP0347041A2 (en) 1989-12-20
AU636127B2 (en) 1993-04-22
NO900185D0 (no) 1990-01-12
DE68929566D1 (de) 2010-01-28
ATE452190T1 (de) 2010-01-15
JPH02504521A (ja) 1990-12-20
US5849883A (en) 1998-12-15
NZ229098A (en) 1992-10-28
NO900185L (no) 1990-03-12

Similar Documents

Publication Publication Date Title
DK9290A (da) Praeparat, isaer til forhindring af infektioner hos dyr
DK47189D0 (da) Bredspektret konserveringsmiddel med synergistisk biocidvirkning
MX9705954A (es) Formulaciones y metodos para reducir irritacion de la piel.
DK0611522T3 (da) Synergistiske mikrobicide sammensætninger
LV10203A (lv) Panemiens inficesanas ar AIDS noteiksanai olbaltumvielu kompozicija test-komplekts
UA19303A (uk) Спосіб одержаhhя похідhих 2-аhіліhопіримідиhу
BR0108260A (pt) Método para proteger uma biomolécula, composição biologicamente derivada, e, método para usar luz pulsada de espectro amplo (bspl) para ativar uma proteìna presente em uma composição biologicamente derivada
DK16890D0 (da) Antiviral eller antibakteriel forbindelse og frem gangsmaade til anvendelse heraf
ATE264685T1 (de) Angesäuertes nitrit zur verwendung als antimikrobielles mittel
CA2039194A1 (en) Uses of l-deprenyl and compositions for same
FR2751879B1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
IL88971A0 (en) Disubstituted pyridines,their preparation and pharmaceutical compositions containing them
ATE76579T1 (de) Interferon-zusammensetzungen.
AU2696584A (en) Pharmaceutical compositions of anti-pancreatic inflammatory effect
ES2058451T3 (es) Un metodo para la preparacion de una composicion farmaceutica.
DK1043028T3 (da) Phytase til forebyggelse eller behandling af mastitis
TW368393B (en) Poison bait for controlling noxious insects
WO1992018090A3 (en) Antimicrobial oral compositions
DE69003216T2 (de) Verwendung von somatostatin.

Legal Events

Date Code Title Description
PUP Patent expired